Finder

Specialises in

• Breast

• Skin

Offers

• Face-to-face consultations
• Video and telephone consultations
• Home chemotherapy

About me

Dr Amna Sheri is a Consultant Medical Oncologist
specializing in precision systemic therapies for breast cancer and melanoma.
Utilizing advanced biomarker analysis, she designs highly personalized
treatment pathways incorporating targeted biologicals, antibody-drug conjugates
(ADCs), immunotherapies, and cutting-edge clinical trials. Her practice
balances leading-edge scientific precision with empathetic, holistic patient
care.
Clinical
Excellence & Background
� Specialist Training: Graduated from Imperial College
London (2004); completed higher specialist training in medical oncology at the
Royal Marsden Hospital.
� Research Doctorate: Awarded an MD(Res) by the
Institute of Cancer Research (ICR) for research focused on predicting outcomes
following pre-surgery (neoadjuvant) therapy.
� Consultant Experience: Appointed Consultant Medical
Oncologist at the Royal Free London NHS Foundation Trust in 2015.
Key Areas
of Expertise
� Biomarker-Driven & Pre-Surgery (Neoadjuvant) Care:
Advanced molecular profiling to tailor pre- and post-surgery therapies,
optimizing tumour shrinkage while minimizing unnecessary side effects.
� Clinical Trials & Research Integration: Directly connects patients to emerging drug developments and clinical trials (ADCs, AKT inhibitors, CDK4/6 therapies) and academic research (ctDNA liquid biopsies for early recurrence tracking, Immunotherapy toxicity).
� Immunotherapy Toxicity Leadership: Leads a specialized
Multidisciplinary Team (MDT) alongside organ specialists (gastroenterology,
endocrinology, rheumatology) to proactively manage and minimize treatment side
effects.
� Complex & Young Women's Breast Cancer: Tailored, compassionate treatment plans for young women and pregnancy-associated cases,
balancing aggressive oncology strategies with fertility preservation, bone health and
long-term quality of life.
Treatments
& Modalities Offered
� Systemic Therapies: Chemotherapy, targeted biologicals, and personalized endocrine/hormone and targeted regimens, antibody drug conjugates.
� Immunotherapies: Modern checkpoint inhibitors and Bispecifc antibodies tailored
for breast cancer and melanoma.
� Precision Second Opinions: In-depth review of
biomarker testing, ctDNA interpretation, and personalized strategy design.

Areas of interest

Breast Cancer (Early, Advanced, Young Women, Pregnancy-Associated); Melanoma; Immunotherapy & Biomarker-Driven Targeted Therapies; Biomarker-Driven & Neoadjuvant Care;
Young Women's & Complex Breast Cancer; Immunotherapy Toxicity Leadership; Clinical Trials & Research Integration; Precision Second Opinions;

Medical secretaries

• Michelle Jones
• The London Oncology Clinic 95 Harley Street London W1G 6AF
• 020 7317 2533
• michelle.jones2@hcaconsultant.co.uk